COMPOUND > MELANOTAN > ABOUT

About Melanotan Source

TIER 01 / WHAT THIS SITE IS

What This Site Is


Melanotan Source is an independent editorial project that publishes summaries of the peer-reviewed research literature on melanotan — Melanotan I (afamelanotide) and Melanotan II. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier 'source' is an editorial position — we are the source record of the melanotan research literature, indexed and cited. It does not imply we are a supplier, vendor, or distributer of any compound. The site has no commercial relationship with any manufacturer, seller, or distributor of peptide compounds.


TIER 02 / WHAT THIS SITE IS NOT

What This Site Is Not


We are not a telehealth service, a compounding pharmacy, or a clinical provider. We do not fill prescriptions. We do not recommend compounds for any use. We do not direct readers to sources of any compound. The negative terms — buy melanotan, melanotan for sale, melanotan supplier, melanotan vendor — do not apply to this site in any sense.

The melanotan research literature includes both promising preclinical and Phase I clinical findings AND serious documented adverse events (renal infarction, rhabdomyolysis, dysplastic nevi, and mucosal malignant melanoma in case reports of self-administered uncontrolled use). We document both tiers of the evidence equally. A reader who wants only the positive findings from this record is not reading the full record.


TIER 03 / EDITORIAL STANDARDS

Editorial Standards


Every quantitative claim on this site maps to a numbered citation in the reference index. Every citation is PubMed-indexed or peer-reviewed journal-indexed. We do not write findings not in the published literature. We do not recommend doses for human use.

The site uses the technical-trust voice: spare, specific, subject-verb-object. Data first. Attribution after. The drill-down organization — breadcrumb paths, parent-metric strips, expanding disclosure tiers — reflects the hierarchical structure of the science itself: from receptor to cascade to clinical outcome to adverse event. The reader controls how deep they drill.

If you identify a factual error or a citation that resolves incorrectly, the contact page is open. We update content when the published literature updates.